Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456885 · ClinicalTrials.gov registry record · Phase 4
The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
A Phase 4 study of Obesity and Impaired Glucose Tolerance, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT00456885 is a Phase 4 study of Obesity and Impaired Glucose Tolerance that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 41 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00456885, a Phase 4 study of Obesity and Impaired Glucose Tolerance, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will look at the effect of exenatide, a drug which has been approved for the treatment of type 2 diabetes, on body weight, appetite and energy expenditure among moderately obese women without diabetes. The study is 35 weeks long and includes 19 outpatient visits. Participants will receive exenatide for 16 weeks and placebo for 16 weeks with a 3 week rest period in between. Neither participants nor investigators will know whether exenatide or placebo is being administered. Participants will be started randomly on either exenatide or placebo. Our hypothesis is that treatment with exenatide will curb appetite and lead to weight loss and may lead to changes in energy expenditure.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG exenatide
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00456885
The ClinicalTrials.gov registry entry for NCT00456885 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00456885 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00456885 about?
NCT00456885 is a clinical study titled "The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women". This study will look at the effect of exenatide, a drug which has been approved for the treatment of type 2 diabetes, on body weight, appetite and energy expenditure among moderately obese women without diabetes. The study is 35 weeks long and includes 19 outpatient visits. Participants will receiv...
What is the current status of trial NCT00456885?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2007-04. Estimated completion is 2010-09.
What conditions does trial NCT00456885 study?
This clinical trial studies the following conditions: Obesity, Impaired Glucose Tolerance.
What interventions are being tested in trial NCT00456885?
The interventions under investigation include: Placebo (DRUG), exenatide (DRUG).
Who is sponsoring clinical trial NCT00456885?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00456885 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.